SELECT PUBLICATIONS

Escudier B et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). Proc ASCO 2006;Abstract 4501.

Escudier B et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO 2005;Abstract 4510.

Hudes G et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Presentation. Proc ASCO 2006;Abstract LBA4.

Motzer RJ et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-á) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proc ASCO 2006a;Abstract LBA3.

Motzer RJ et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006b;295(21):2516-24. Abstract

Shaheen PE et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Proc ASCO 2006;Abstract 4605.

Tamaskar I et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. Proc ASCO 2006;Abstract 4597.

 

 

 

 

 

 

 

Home

Editor’s Note:
Renal cell fireworks

Interviews
Nicholas J Vogelzang, MD
- Select publications

Ronald M Bukowski, MD
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office